Topic:

Europe

Latest Headlines

Latest Headlines

Cellnovo partners with TypeZero in major NIH-backed artificial pancreas trial in Type 1 diabetics

Paris-based Cellnovo Group has partnered with TypeZero Technologies to be part of a previously announced clinical trial of an artificial pancreas that's being backed by a $12.8 million grant from the U.S. National Institutes of Health. Cellnovo's connected insulin patch pump will be used in conjunction with TypeZero's inControl AP software and a Dexcom continuous glucose monitor to form the whole of the artificial pancreas system being tested.

U.K. public life science investment hits £1.3B; Mission bags £60M; Pierre Fabre starts VC fund

In this week's EuroBiotech Report, the London Stock Exchange said public life science investment hit a decade-long high in 2015. A bumper year for follow-on offerings drove the total investment up to £1.3 billion ($1.9 billion), a significant sum that masks the dearth of major IPOs. And more.

InflaRx starts preparation for PhIIb septic organ dysfunction trial after clearing safety study

InflaRx has posted positive safety data from a Phase IIa trial of its treatment for early septic organ dysfunction. Having met the primary endpoints in the study, InflaRx is now sifting through the data ahead of planned meetings with regulators to discuss the design of a Phase IIb trial.

Pierre Fabre starts open-ended collaborative translational R&D fund

Pierre Fabre has entered the world of biotech investing with a vehicle for equity funding and R&D co-financing deals. But, while an open-ended sum of cash is theoretically available, the French firm is placing as much emphasis on the support it can provide fledgling biotechs at a critical stage of drug development.

Mission set to push Parkinson's, cancer drugs into PhI after scooping £60M

Mission Therapeutics is gearing up to move drugs from its Parkinson's disease and immuno-oncology programs into the clinic. The activity is to be fuelled by a £60 million ($88 million) investment, which has given the company the financial firepower to take a pair of programs based on its DUB platform through to Phase I data readouts over the next three to four years.

U.K. keeps funding for clinical research sites flat through to 2022

The United Kingdom government is to pump £112 million ($160 million) into a network of clinical research facilities from 2017 to 2022. Officials see the investment bolstering the attractiveness of the U.K. as a location for early-stage research, but the facilities will need to pull off these improvements without the benefit of access to a meaningfully bigger pot of money.

Follow-on bonanza drives U.K. investment in life science stocks past £1B

At first glance, 2015 looks like the year the London Stock Exchange turned its back on biotech once again. Acacia Pharma and Shield Therapeutics both tried and failed to be 2015's Circassia, the big success story of 2014, leaving AIM listings and outliers such as PureTech as the most notable London IPOs of the year. And yet, from another angle, 2015 looks like a landmark year.

Samsung's Benepali biosimilar wins first EU sales in Norway

Norway became the first overseas country to approve the Enbrel biosimilar made by Samsung Bioepis for sale, coming two weeks after the drug, Benepali, was approved by the European Commission.

UPDATED: Sanofi chops into R&D operations in France in latest retrenchment

Following up on a plan to slim operations and cut $1.6 billion in costs, the new CEO at Paris-based Sanofi is taking an ax to 500 jobs, according to press reports.

CDMO Vetter finishes German IT facility

Years ago, German CDMO Vetter determined that in addition to building out its manufacturing capacity, it needed to expand its IT infrastructure to continue to satisfy clients. Now after two years, Vetter has wrapped up work on a 91,500-square-foot multipurpose facility in Schuetzenstrasse, Germany, that bulks up computing operations.